Xavier T. Reveles - 18 Sep 2023 Form 3 Insider Report for bioAffinity Technologies, Inc. (BIAF)

Role
Chief Operating Officer
Signature
/s/ Xavier Trinidad Reveles
Issuer symbol
BIAF
Transactions as of
18 Sep 2023
Net transactions value
$0
Form type
3
Filing time
25 Sep 2023, 18:12:15 UTC
Next filing
02 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BIAF Common Stock 3,619 18 Sep 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BIAF Stock Option (Right to Buy) 18 Sep 2023 Common Stock 2,857 $7.70 Direct F2
holding BIAF Stock Option (Right to Buy) 18 Sep 2023 Common stock 1,428 $7.70 Direct F2
holding BIAF Stock Option (Right to Buy) 18 Sep 2023 Common Stock 1,428 $7.70 Direct F2
holding BIAF Stock Option (Right to Buy) 18 Sep 2023 Common Stock 2,142 $7.70 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This restricted stock award was granted on November 17, 2022 and vest pro rata monthly over one year.
F2 This stock option is fully vested and reflects a stock split that occurred on June 23, 2022.

Remarks:

Exhibit List - Exhibit 24.1: Power of Attorney (Xavier Reveles)